Polycythemia Vera | Treatment Algorithms: Claims Data Analysis | US | 2022

MARKET OUTLOOK

Polycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of which has its own treatment approach and prognosis. Although current pharmacologic treatment is considered adequate for a relatively large group of PV patients, certain population segments are associated with substantial unmet need. As such, there is commercial opportunity for therapies able to differentiate from the current standard of care. Understanding the treatment dynamics is critical to identifying those opportunities.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PV patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PV patients?
• How has ruxolitinib (Incyte’s Jakafi) been integrated into the treatment algorithm, and what is its source of business?
• What percentage of PV patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
• What percentage of PV patients are treated with monotherapy versus combination therapy? What are the most used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: BMS, Incyte, Roche

Key drugs: Hydroxyurea, peg-interferon-alpha, ruxolitinib

SOLUTION ENHANCEMENT

The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.